Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Boeing shares are under pressure after the FAA delayed 737 MAX 10 certification while reviewing a flight-management software glitch that can disrupt automated guidance in a specific landing scenario. Traders are divided: some call the issue manageable and the selloff excessive, while others see it as another sign of Boeings quality and management problems and worry about further certification delays.

AstraZenecas $2 billion convertible-equity investment and clinical collaboration with Summit have drawn attention, with traders viewing the deal as a major funding boost and vote of confidence in ivonescimab. Some speculate it could precede an acquisition, while others stress that it is an equity investmentnot a buyoutand that FDA approval and clinical outcomes remain uncertain.

Kodiaks Phase 3 DAYBREAK study met its primary goals for two wet AMD drug candidates, with vision results comparable to Eylea and Zenkuda showing potential for longer dosing intervals; the results support a planned FDA filing. Traders cheered the clinical progress and discussed a possible short squeeze, while others questioned the rallys valuation and flagged financing, dilution, and regulatory risks.

Navitas selection for a U.S. Army program to develop next-generation 10 kV silicon-carbide power semiconductors is drawing attention as a technology and domestic-manufacturing validation. Traders are bullish on the longer-term potential and speculate about a short squeeze, while others note that the awards financial terms are undisclosed and near-term revenue is uncertain.

FHFAs move to let Fannie Mae and Freddie Mac use VantageScore alongside FICO scores has raised concerns that competition could weaken FICOs long-standing mortgage-scoring position and pricing power. Traders debate whether the shift signals lasting damage to the companys moat or an overreaction, with some seeing a buying opportunity while others expect further pressure.

HBARs sharp rally and heavy volume are driving attention, with traders pointing to IBM-related enterprise integration and Hederas AI ties, including NVIDIAs agent-safety platform, as possible catalysts. Others question whether there is a clear new trigger and debate whether the move can hold or will give way to profit-taking and a pullback.

Zebecs payroll and payments expansionincluding enterprise USDC payroll on Stellar and its card/SuperApp ecosystemis fueling renewed interest in the tokens real-world utility. Bulls see adoption and staking as long-term supports, while skeptics argue partnerships have yet to translate into enough user activity or token demand to lift the price consistently.

IBRX is drawing attention after a volatile move higher and pullback, with traders debating whether short covering or routine trading and biotech-sector moves drove the price action. The discussion also centers on speculation about forthcoming ANKTIVA updates and label expansions, but no new catalyst is confirmed in the messages.

A volatile XLM rebound and repeated attempts to sustain a breakout are driving attention, with traders pointing to institutional payments and tokenization adoptionincluding DTCC-related hopesas a bullish narrative. Others argue rallies keep fading into selling and that XLM continues to lag or follow Bitcoin, leaving debate over whether the move can hold.

MLTX is drawing attention amid a steep selloff that traders link to the equity raise, disappointing or less-differentiated-than-hoped IZAR results, and waning confidence in management. The main near-term focus is the expected HS BLA filing, which bullish traders see as a key de-risking catalyst while skeptics question the drugs competitive edge and MoonLakes plans to commercialize it independently.